Novo Nordisk Launches Phase 3 Trial Testing Ziltivekimab for Coronary Plaque Reduction After Heart Attack
核心洞察
Novo Nordisk has initiated a Phase 3 trial evaluating ziltivekimab, an anti-inflammatory drug, for reducing coronary atherosclerosis in patients following acute myocardial infarction.
The quadruple-masked, placebo-controlled study will test monthly subcutaneous injections of ziltivekimab against placebo over a 15-month treatment period.
This trial represents Novo Nordisk's expansion beyond diabetes and obesity into cardiovascular risk reduction, potentially opening a new revenue stream alongside GLP-1 therapies.
Novo Nordisk has announced the launch of a Phase 3 clinical trial investigating whether its experimental anti-inflammatory drug ziltivekimab can reduce coronary plaque buildup in patients who have suffered acute myocardial infarction. The study, titled "Effects of Ziltivekimab Versus Placebo on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction," aims to demonstrate that targeting inflammation can slow or reverse plaque accumulation, potentially reducing the risk of repeat cardiac events.
Trial Design and Treatment Protocol
The interventional study employs a randomized, quadruple-masked, parallel-group design comparing ziltivekimab plus standard care against placebo plus standard care. In this quadruple-masked approach, patients, physicians, study staff, and outcome assessors remain blinded to treatment allocation throughout the trial duration.
Ziltivekimab is administered as a monthly subcutaneous injection, designed to lower vessel inflammation and reduce plaque burden. The drug is not yet approved in any jurisdiction, making this Phase 3 trial critical for its potential future commercialization and clinical application.
Study Timeline and Recruitment
The clinical trial was first submitted on November 27, 2025, marking the formal initiation of this cardiovascular program. The study is currently in the recruitment phase, with each participant undergoing approximately 15 months of treatment. The most recent update was filed on December 22, 2025, confirming that trial details and status remain current.
Primary completion is expected to occur following the treatment period, with final completion scheduled after imaging assessments and follow-up analyses are completed and analyzed.
Strategic Implications for Novo Nordisk
This trial represents a significant expansion of Novo Nordisk's therapeutic focus beyond its established diabetes and obesity franchises into high-value cardiovascular risk reduction. Success in this study could support a higher long-term growth trajectory and valuation multiple for the company if results prove positive.
The cardiovascular indication would add a new revenue stream alongside Novo Nordisk's existing GLP-1 therapies, potentially strengthening the company's position in cardiometabolic medicine. The active recruitment status should bolster confidence in the company's pipeline development capabilities.
Industry Impact and Competitive Landscape
A positive outcome demonstrating plaque reduction could establish inflammation-targeting drugs as a new paradigm for secondary prevention following myocardial infarction. This development would likely raise the bar for future standard of care protocols and intensify research and development focus on inflammation pathways across the pharmaceutical industry.
Competitors in the cardiometabolic drug space, including major pharmaceutical companies focused on heart and kidney disease, are expected to monitor this trial closely. The results could influence future drug development strategies and competitive positioning in the cardiovascular therapeutics market.
The trial continues to recruit patients, with additional details available through the ClinicalTrials.gov portal as the study progresses toward its primary completion milestone.